the Company completed the acquisition of Alimera Sciences. The transaction significantly expands the scope and scale of ANI’s ...

Ani Pharmaceuticals ( (ANIP) ) has released its Q3 earnings. Here is a breakdown of the information Ani Pharmaceuticals presented to its ...

“I am very pleased to report our third quarter results as we continue to execute against our purpose of ‘Serving Patients, Improving Lives,'” said Nikhil Lalwani, President & CEO of ANI ... the ...

ANIP may be acquired soon with a potential offer exceeding $8 billion and contingent on FDA approval of a new drug filed in ...

ANI’s Estradiol Gel ... including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are identified by the words “believe ...

"With the FDA approval and commercialization of Estradiol Gel, 0.06%, we are pleased to bring another limited-competition ...

Update 2:40pm: Adds ANI Pharma response, updates shares. Alimera Sciences (NASDAQ:ALIM) pared an earlier drop to 6% after it said it filed a lawsuit against ANI Pharmaceuticals (ANIP) to compel ...

ANI’s Estradiol Gel ... including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are identified by the words ...

ANI is focused on delivering sustainable growth by scaling up ... including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are ...

ANI Pharmaceuticals (NASDAQ:ANIP) announced that following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application, the company launched Estradiol Gel, 0.06% ...